Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors

Transplant Immunology

Volumn 4, Issue 4, 1996, Pages 319-323

  Hassan, H T ^a   Stockschlader M ^a   Schleimer, B ^a   Kruger W ^a   Zander, A R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; COMPARATIVE STUDY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LEUKAPHERESIS; PRIORITY JOURNAL; STEM CELL;

EID: 0030463127     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(96)80054-2     Document Type: Article

References (22)

1. 1 Kessinger A. Do autologous peripheral blood cell transplants provide more than hematopoietic recovery? Stem Cells 1995; 13: 351-54,
2. 2 Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilised by recombinant human G-CSF. Blood 1995; 85: 1655-58.
3. 3 Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-65.
4. 4 Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilised by filgrastim (G-CSF). Blood 1995; 85: 1666-72.
5. 5 Tanaka J, Kasai M, Imamura M, Asaka M. Clinical application of allogeneic peripheral blood stem cells transplantation. Ann Hematol 1995; 71: 265-69.
6. 6 Körbling M, Huh YO, Durett A et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+Thy-1dim) and lymphoid subsets and possible predictors of engraftment and GVHD. Blood 1995; 86: 2842-48.
7. 7 Tjonnfjord GE, Steen R, Evensen SA, Thorsby E, Egeland T. Characterisation of CD34+ peripheral blood cells from healthy adults mobilised by recombinant human G-CSF. Blood 1994; 84: 2795-801.
8. 8 Korngold R. Pathophysiology of GVHD directed to minor histocompatibility antigens. Bone Marrow Transplant 1991; 7 (suppl 1): 38-41.
9. 9 Nimer SD, Giorgi J, Gajewski JL et al. Selective depletion of CD8+ cells for prevention of GVHD after bone marrow transplantation: a randomised controlled trial. Transplantation 1994; 57: 82-87.
10. 10 Champlin R. T-cell depletion for allogeneic marrow transplantation: innovations to enhance engraftment and graft versus leukemia. Bone Marrow Transplant 1995; 15 (suppl 1): S104-S111.
11. 11 Bacigalupo A, Van Lint MT, Valbonesi M et al. Thiotepa cyclophosphamide followed by G-CSF mobilised allogeneic peripheral blood cells in adults with advanced leukemia. Blood 1996; 88: 353-57.
12. 12 Civin CI, Gore SD. Antigenic analysis of hematopoiesis: a review. J Hematother 1993; 2: 137-44.
13. 13 Spitzer G, Verma D, Fisher R et al. The myeloid progenitor cell -its value in predicting hematopoietic recovery after autologous BMT. Blood 1980; 55: 317-23.
14. 14 Douay L, Gorin N, Mary J et al. Recovery of CFU-GM from cryopreserved marrow and in vivo evaluation after autologous bone marrow transplantation are predictive of engraftment. Exp Hematol 1986; 14: 358-65.
15. 15 Roodman GD, Le Maistre CF et al. CFU-GEMM correlate with neutrophil and platelet recovery in patients receiving autologous marrow transplantation after high-dose melphalan chemotherapy. Bone Marrow Transplant 1987; 2: 165-73.
16. 16 Rowley SD, Piantadosi S, Santos GW. Correlation of hematologic recovery with CFU-GM content of autologous bone marrow grafts treated with 4-hydroperoxy-cyclophosphamide-purged bone marrow. Blood 1987; 70: 271-95.
17. 17 To LB, Roberts M, Haylock DN et al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-84.
18. 18 Grigg A, Begley CG, Juttner CA et al. Effect of peripheral blood progenitor cells mobilized by filgristim (G-CSF) on platelet recovery after high-dose chemotherapy. Bone Marrow Transplant 1993; 11 (suppl 2): 23-29.
19. 19 To LB, Dyson PG, Brandford AL et al. CFU-mix are no better than CFU-GM in predicting reconstitutive capacity of peripheral blood stem cells collected in the very early remission phase. Exp Hematol 1987; 15: 351-54.
20. 20 Olivieri A, Offidani M, Ciniero L et al. Optimization of the yield of PBSC for autotransplantation mobilized by high-dose chemotherapy and G-CSF: proposal for a mathematical model. Bone Marrow Transplant 1994; 14: 273-78.
21. 21 Reiffers J, Faberes C, Bioron JM et al. Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment. J Hematother 1994; 3: 185-91.
22. 22 Hassan HT, Stochschläder M, Krügger W, Hoffknecht MM, Zander AR. G-CSF administration following peripheral blood selected CD34-positive cells autologous transplantation accelerates haematological recovery after myeloablative therapy. Br J Haematol 1996; 92: 1027-29.